A patient presented with Candida auris vertebral osteomyelitis, a rare and challenging infection given its multidrug resistance and high mortality. Diagnosis involved identifying C. auris, also known as Candidozyma auris, as the causative agent of the bone infection. The treatment regimen included combination antifungal therapy, followed by a novel long-acting echinocandin, highlighting an innovative approach to managing this difficult-to-treat fungal osteomyelitis. This case underscores the importance of prompt and effective antifungal strategies for emerging multidrug-resistant pathogens.
Key note: Early and aggressive combination antifungal therapy, including novel agents, is crucial for managing severe Candida auris infections like osteomyelitis.